Epidiolex set for autumn launch after US Food and Drug Administration gives approval
A treatment for childhood epilepsy developed by a UK firm has been approved by US regulators and will become the first cannabis-based medicine on the American market.
Epidiolex, made by GW Pharmaceuticals, is set to be launched in the autumn after being approved by the US Food and Drug Administration (FDA) for the treatment of two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome, for patients from the age of two.
from US news | The Guardian https://ift.tt/2tCkwvk
No comments:
Post a Comment